Compass Therapeutics (CMPX) vs Canton Strategic (CNTN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Canton Strategic (CNTN) has outperformed Compass Therapeutics (CMPX) over the past year, losing 34.6% versus a loss of 74.8%. Compass Therapeutics is the larger company by market cap ($177.1 million vs $165.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CMPX | CNTN |
|---|---|---|
| Share price | $0.9834 | $2.08 |
| Market cap | $177.10M | $165.74M |
| 1-day change | -3.59% | -7.96% |
| YTD return | -81.69% | -31.35% |
| 1-year return | -74.78% | -34.59% |
| 5-year return | -68.22% | — |
| EPS (TTM) | $-0.38 | $-0.09 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.88 | $6.89 |
| 52-week low | $0.829 | $1.75 |
| Distance from 52-week high | -85.71% | -69.81% |
| Analyst consensus | buy | — |
| Avg. price target upside | +454.20% | — |
| Average volume | 4.06M | 758.86K |
| Shares outstanding | 180.09M | 79.68M |
| Employees | 39 | 12 |
| Sector | Health Care | Healthcare |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CNTN has outperformed CMPX by 40.2 percentage points over the past year.
- The two companies sit in different sectors: Compass Therapeutics in Health Care and Canton Strategic in Healthcare.
About Compass Therapeutics
CMPX stock →Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), which are critical to angiogenesis and tumor vascularization.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 39 employees
About Canton Strategic
CNTN stock →Canton Strategic Holdings, Inc. engages in the institutional blockchain adoption and digitization of financial markets in the United States.
Healthcare · Biotechnology · 12 employees
CMPX vs CNTN FAQ
Which is bigger, Compass Therapeutics or Canton Strategic?
Compass Therapeutics (CMPX) is larger, with a market capitalization of $177.10M compared with $165.74M for Canton Strategic (CNTN).
Which stock has performed better over the past year, CMPX or CNTN?
CNTN returned -34.59% over the past 12 months, compared with -74.78% for CMPX (price return, excluding dividends). Past performance does not predict future results.
Are Compass Therapeutics and Canton Strategic in the same industry?
No. Compass Therapeutics is in the Health Care sector, while Canton Strategic is in Healthcare.